You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety

Golubchik, Pavela,d; Golubchik, Lilyae; Sever, Jonathan M.a,d; Weizman, Abrahamb,c,d

International Clinical Psychopharmacology:
doi: 10.1097/YIC.0000000000000034
Original Articles
Abstract

The objective of this study was to assess the response of subsyndromal separation anxiety (SSSA) symptoms to methylphenidate (MPH) treatment in patients with attention-deficit/hyperactivity disorder (ADHD). A group of patients with ADHD and SSSA (n=42), aged 8–17 years, received 12 weeks of MPH treatment. The severity of SSSA symptoms was assessed using appropriate scales including the Screen for Child Anxiety Related Emotional Disorders and the specially designed Child and Adolescent Separation Anxiety Scale (CASAS). The severity of ADHD symptoms was assessed using the ADHD Rating Scale. The severity of ADHD and separation anxiety reduced significantly and significant positive correlations were found between the changes in ADHD Rating Scale and the total CASAS scores (P=0.012), as well as other relevant subscales of Screen for Child Anxiety Related Emotional Disorders and CASAS. The MPH-related attenuation in the severity of ADHD was associated with a corresponding improvement in separation anxiety related to school. SSSA symptomatology may be secondary to ADHD and thus the alleviation in ADHD symptoms achieved by MPH treatment results in corresponding relief in separation anxiety.

Author Information

aChild and Adolescent Outpatient Clinic

bResearch Unit, Geha Mental Health Center

cFelsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva

dSackler Faculty of Medicine, Tel Aviv University, Tel Aviv

eAdult Eating Disorder Department, Sheba Medical Center, Tel Hashomer, Israel

All supplementary digital content is available directly from the corresponding author.

Correspondence to Pavel Golubchik, MD, Child and Adolescent Outpatient Clinic, Geha Mental Health Center, PO Box 102, Petah Tikva 49100, Israel Tel: +972 3 9258270; fax: +972 3 9523598; e-mail: pavelgo@gmail.com

Received January 13, 2014

Accepted February 25, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins